Pulse Biosciences will showcase late‑breaking 6‑ and 12‑month follow‑up data from its first‑in‑human feasibility study of the nPulse Cardiac Catheter Ablation System at the 31st Annual AF Symposium, scheduled for February 5‑7, 2026. The presentation will detail safety and efficacy outcomes from a European cohort of 150 patients treated with the company’s nanosecond pulsed‑field ablation (nsPFA) technology, a first‑in‑class approach that delivers non‑thermal, high‑frequency electrical pulses to ablate atrial tissue while sparing surrounding structures.
Pulse’s pivot away from dermatology in 2022 has positioned the company to focus on the multi‑billion‑dollar atrial fibrillation market. The company has received FDA Investigational Device Exemption approvals for both its cardiac surgery and catheter nsPFA platforms and is preparing a pivotal U.S. study in the first quarter of 2026. Despite a Q3 2025 GAAP net loss of $19.4 million and $95.2 million in cash and equivalents, the company generated $86 thousand in revenue from a limited market release, underscoring the early‑stage nature of its commercial operations.
The nsPFA platform differentiates Pulse from established competitors such as Boston Scientific’s FARAPULSE™ and Medtronic’s PulseSelect, offering lower total energy delivery and reduced collateral tissue damage. Positive data at the AF Symposium could accelerate regulatory discussions, attract partnership interest, and bolster investor confidence, positioning Pulse to capture a share of the atrial fibrillation ablation market dominated by thermal ablation technologies.
CEO Paul LaViolette emphasized the significance of the data, stating, “We believe our novel and proprietary non‑thermal nPulse technology offers significant advantages in safety, efficacy, and speed compared to traditional radiofrequency ablation.” He added, “Pulse Biosciences is the first company to advance PFA into the cardiac surgical field for the treatment of AF,” highlighting the company’s pioneering role and its potential to reshape the ablation landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.